ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0983

Outcomes Following Antimalarial Withdrawal in Patients with Quiescent Systemic Lupus Erythematosus

Danae Papachristos1, Dafna Gladman2, Jiandong Su3 and Murray Urowitz4, 1University Health Network, Toronto, ON, Canada, 2Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 4University Health Network, University of Toronto, Toronto, ON, Canada

Meeting: ACR Convergence 2020

Keywords: Disease Activity, Disease-Modifying Antirheumatic Drugs (Dmards), Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Saturday, November 7, 2020

Session Title: SLE – Diagnosis, Manifestations, & Outcomes I: Morbidity (0980–0984)

Session Type: Abstract Session

Session Time: 5:00PM-5:50PM

Background/Purpose: Antimalarial medications (AMs) are central to the management of SLE, affording numerous clinical benefits including the reduction of disease flare. However, little is known about the effects of AM withdrawal in patients who have achieved prolonged disease quiescence. We aimed to investigate the rate of flare in lupus patients who withdrew their AM after achieving clinical remission for at least one year, compared to those who continued therapy. Furthermore, we aimed to compare flare rates in cases who tapered AM versus abruptly withdrew.

Methods: Using the University Lupus Clinic long-term observational cohort study database, we identified 1573 lupus patients ever treated with AM. Cases were defined as those who achieved clinical remission for at least one year then ceased their AM (n = 165). Index date was defined as the date of complete AM cessation. Controls were defined as patients who achieved clinical remission for at least one year and continued AM. Controls were matched according to the duration of antimalarial therapy before the start of clinical remission and the duration of therapy from remission date to case index date (Figure 1). All patients were required to have at least two years of follow up. Of 96 cases with adequate follow up, 88 were successfully matched to one control and 85 to a second control, resulting in a near 1:2 match. In total, there were 88 cases and 173 controls.

Results: Patient characteristics for cases (withdrew AM) and controls (continued AM) are presented in Table 1. Disease flare occurred in 61.4% of cases compared to 45.1% of controls (p = 0.002, Figure 2). The most common types of flare were skin and musculoskeletal flares. Reasons for AM withdrawal included self-cessation (feeling well, pregnancy, medication concerns), toxicity (retinal, mucocutaneous, cardiac), disease quiescence or other reasons such as side effects requiring investigation. Retinal toxicity as defined by the SLICC damage index occurred in 1.9% of patients. Over half of patients who withdrew AM later restarted it, typically due to disease flare. Following recommencement for flare, most patients (88%) recaptured control or improved, while 12% had further flares. Regarding patients who withdrew AM, 42% tapered and 58% ceased abruptly (Table 1). The median duration (months) spent on AM from one year after clinical remission to cessation was expectedly longer in the taper group (29.2 months) compared to the abrupt withdrawal group (11.2 months). Patients who tapered had significantly fewer flares (45.9%), similar to the rate for controls (45.1%), when compared to those who withdrew abruptly (72.6%; p = 0.01, Figure 2). Additionally, fewer patients in the taper group restarted AM following cessation (37.8%) compared to the abrupt withdrawal group (62.7%; p = 0.02).

Conclusion: Antimalarial medications aid in preventing disease flare even in patients who have achieved prolonged clinical remission. For those who withdraw therapy, tapering results in lower rates of disease flare, similar to those seen in patients who continue AMs. Hence, except in the setting of toxicity, cessation of antimalarial therapy in patients with prolonged disease quiescence is feasible using a slow taper.

Figure 1: Definition and matching process for cases and controls

Figure 2: Rates of various flare types (%) including any SLEDAI flare, SLEDAI increase by 4 or more, clinical SLEDAI flare and immunological flare in (A) patients who ceased AM compared to patients who continued AM and (B) patients who weaned to AM to cessation compared to patients who abruptly withdrew AM


Disclosure: D. Papachristos, None; D. Gladman, AbbVie, 2, 5, Amgen, 2, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5, Bristol-Myers Squibb, 5, Gilead, 5, Galapagos, 5, Celgene, 2, 5, Eli Lilly, 2, 5; J. Su, None; M. Urowitz, None.

To cite this abstract in AMA style:

Papachristos D, Gladman D, Su J, Urowitz M. Outcomes Following Antimalarial Withdrawal in Patients with Quiescent Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/outcomes-following-antimalarial-withdrawal-in-patients-with-quiescent-systemic-lupus-erythematosus/. Accessed April 11, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/outcomes-following-antimalarial-withdrawal-in-patients-with-quiescent-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.